DR. JONATHAN T WONG, M.D.
Urology at Miranda Ave, Palo Alto, CA
License number
California C38257
Category
Radiology
Type
Urology
Address
Address
2
3801 Miranda Ave, Palo Alto, CA 94304
7852 Tanias Ct, Aptos, CA 95003
7852 Tanias Ct, Aptos, CA 95003
Phone
(650) 493-5000
(831) 687-0181
(831) 687-0181
Professional information
Software Engineer - Independent Consulting
Position:
Software Engineer at Xoom Corporation, Software Engineer - Independent Consulting at Zelos Software
Location:
San Francisco Bay Area
Industry:
Computer Software
Work:
Xoom Corporation
- san francisco since Feb 2013
-
Software Engineer
Zelos Software
since Apr 2010
-
Software Engineer - Independent Consulting
Mercedes-Benz Research & Development North America, Inc.
- Palo Alto, CA Apr 2010 - Jun 2012
-
Systems Engineer
RTZ Associates
Jul 2009 - Apr 2010
-
Software Development
University of California
Nov 2007 - Jun 2009
-
Computer Technician and Server Administrator/Webmaster
Apple Inc
Jun 2008 - Dec 2008
-
Apple Care - Technical Support Agent
Education:
University of California, Davis 2004 - 2009
Bachelor of Science (BS), Computer Science and Engineering
Bachelor of Science (BS), Computer Science and Engineering
Languages:
Cantonese/Chinese, English
Ex Vivo And In Vivo Expression Of The Thrombomodulin Gene For The Treatment Of Cardiovascular And Peripheral Vascular Diseases
US Patent:
7713522, May 11, 2010
Filed:
Jul 28, 2008
Appl. No.:
12/219714
Inventors:
Lakshman R. Sehgal - Monarch Beach CA, US
Jonathan Wong - Palo Alto CA, US
Jonathan Wong - Palo Alto CA, US
Assignee:
BioVec, LLC - Chicago IL
International Classification:
A01N 63/00, A61K 39/325, A61K 31/715, C12H 15/86, C07H 21/04
US Classification:
424 936, 4242331, 514 44, 435456, 536 235, 536 241, 536 242
Abstract:
The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel ex vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a gutless adenovirus vector carrying a transgene, such as a gene encoding TM protein or its variant.
Ex Vivo And In Vivo Expression Of The Thrombomodulin Gene For The Treatment Of Cardiovascular And Peripheral Vascular Diseases
US Patent:
7803365, Sep 28, 2010
Filed:
Mar 13, 2007
Appl. No.:
11/685474
Inventors:
Lakshman R. Sehgal - Monarch Beach CA, US
Jonathan Wong - Palo Alto CA, US
Jonathan Wong - Palo Alto CA, US
Assignee:
Biovec, LLC - Chicago IL
International Classification:
A01N 63/00, A61K 31/715, A61K 39/235, C07H 21/04, C12N 15/861
US Classification:
424 936, 4242331, 435456, 514 44, 536 235, 536 241, 536 242
Abstract:
The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.
Ex Vivo And In Vivo Expression Of The Thrombomodulin Gene For The Treatment Of Cardiovascular And Peripheral Vascular Diseases
US Patent:
8420075, Apr 16, 2013
Filed:
Mar 30, 2010
Appl. No.:
12/750219
Inventors:
Lakshman R. Sehgal - Monarch Beach CA, US
Jonathan Wong - Palo Alto CA, US
Jonathan Wong - Palo Alto CA, US
Assignee:
Biovec, LLC - Chicago IL
International Classification:
A01N 63/00, A61K 31/715, A61K 39/235, C07H 21/04, C12N 15/861
US Classification:
424 936, 4242331, 435456, 514 44, 536 235, 536 241, 536 242
Abstract:
The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.
Ex Vivo And In Vivo Expression Of The Thrombomodulin Gene For The Treatment Of Cardiovascular And Peripheral Vascular Diseases
US Patent:
7481998, Jan 27, 2009
Filed:
Jan 8, 2007
Appl. No.:
11/650479
Inventors:
Lakshman R. Sehgal - Monarch Beach CA, US
Jonathan Wong - Palo Alto CA, US
Jonathan Wong - Palo Alto CA, US
Assignee:
BioVec, LLC - Chicago IL
International Classification:
A01N 63/00, A61K 39/235, A61K 31/715, C12N 15/86, C07H 21/04
US Classification:
424 936, 4242331, 514 44, 435456, 536 235, 536 241, 536 242
Abstract:
The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel ex vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a gutless adenovirus vector carrying a transgene, such as a gene encoding TM protein or its variant.
Ex Vivo And In Vivo Expression Of The Thrombomodulin Gene For The Treatment Of Cardiovascular And Peripheral Vascular Diseases
US Patent:
7501114, Mar 10, 2009
Filed:
Jan 8, 2007
Appl. No.:
11/650478
Inventors:
Lakshman R. Sehgal - Monarch Beach CA, US
Jonathan Wong - Palo Alto CA, US
Jonathan Wong - Palo Alto CA, US
Assignee:
Biovec, LLC - Chicago IL
International Classification:
A01N 63/00, A61K 39/325, A61K 31/715, C12H 15/86, C07H 21/04
US Classification:
424 936, 4242331, 514 44, 435456, 536 235, 536 241, 536 242
Abstract:
The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.
In Vivo And Ex Vivo Gene Transfer Into Renal Tissue Using Gutless Adenovirus Vectors
US Patent:
2011030, Dec 15, 2011
Filed:
Jul 11, 2011
Appl. No.:
13/180378
Inventors:
Lakshman R. SEHGAL - Monarch Beach CA, US
Jonathan Wong - Palo Alto CA, US
Jonathan Wong - Palo Alto CA, US
Assignee:
BIOVEC, LLC - Chicago IL
International Classification:
A61F 2/04, A61M 25/10, A61P 9/10, A61P 9/12, A61K 31/711, A61P 13/12
US Classification:
623 2365, 514 44 R, 604509
Abstract:
A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
In Vivo And Ex Vivo Gene Transfer Into Renal Tissue Using Gutless Adenovirus Vectors
US Patent:
8048410, Nov 1, 2011
Filed:
May 12, 2010
Appl. No.:
12/778360
Inventors:
Lakshman R. Sehgal - Monarch Beach CA, US
Jonathan Wong - Palo Alto CA, US
Jonathan Wong - Palo Alto CA, US
Assignee:
Biovec, LLC - Chicago IL
International Classification:
A61K 48/00, C07H 21/04
US Classification:
424 932, 536 232, 536 235
Abstract:
A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
In Vivo And Ex Vivo Gene Transfer Into Renal Tissue Using Gutless Adenovirus Vectors
US Patent:
2009023, Sep 24, 2009
Filed:
Jan 26, 2009
Appl. No.:
12/320434
Inventors:
Lakshman R. Sehgal - Monarch Beach CA, US
Jonathan Wong - Palo Alto CA, US
Jonathan Wong - Palo Alto CA, US
Assignee:
BIOVEC, LLC. - Chicago CA
International Classification:
A61K 48/00, A61K 35/76, A61K 31/713, A61K 38/17, A61K 38/44, A61P 1/16, A61P 37/06, C12N 15/861
US Classification:
424 932, 514 44 R, 514 44 A, 514 12, 424 944, 4353201
Abstract:
A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
Jonathan Hanchang Wong, Palo Alto CA - Lawyer
Address:
51 Jordan Pl, Palo Alto 94303
(650) 380-9928
(650) 380-9928
Licenses:
California - Active 2009
Education:
Santa Clara University School of Law
Northwestern University
Northwestern University